Medical/Pharmaceuticals
NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)
TEL-AVIV, Israel, July 30, 2024 /PRNewswire/ -- Neurim Pharmaceuticals
2024-07-30 09:00
4017
Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis
SEONGNAM, South Korea, July 29, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based inSouth Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-...
2024-07-30 06:00
2212
CSafe launches reusable Silverpod pallet shipper to help pharma companies save on disposal costs and hit sustainability targets
New pallet improves cost and operational efficiency while reducing environmental impact; includes real-time visibility with cloud connectivity Key features include: * Made of fully reusable components and recyclable PCM (phase change material) refrigerants * New integrated real-time tracking...
2024-07-30 02:00
2984
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52,...
2024-07-29 23:18
3266
SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™
The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that...
2024-07-29 22:30
2488
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin
SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsChang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant ste...
2024-07-29 20:00
2605
Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ
* Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year * Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year * Net Profit Attributable to the Owners of the Com...
2024-07-29 19:05
5147
EXPOSURE TO WILDFIRE SMOKE GREATLY RAISES RISK OF DEMENTIA DIAGNOSIS
Key Takeaways * Wildfire smoke may be particularly hazardous to brain health, according to a 10-year study of more than 1.2 million southern Californians. * Exposure to wildfire smoke increases the risk of being diagnosed with dementia more than other forms of air pollution. * The risk o...
2024-07-29 19:00
2784
Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA
HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class PD-1/VEGF bispecific antibody drug, 依达方® (generic name: ivonescimab Injection), as a monotherapy for...
2024-07-29 17:26
2524
Global Icon Malala Yousafzai to Headline APACMed's MedTech Forum in Singapore
SINGAPORE, July 29, 2024 /PRNewswire/ -- APACMed is thrilled to announce that Nobel Laureate and global iconMalala Yousafzai will take centre stage at this year's MedTech Forum, taking place onSeptember 5th and 6th at the Suntec Convention Centre. This highly anticipated event focuses squarely on...
2024-07-29 13:44
10616
111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 - Conference Call to Follow
SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will repor...
2024-07-29 13:00
2205
A.MENARINI, CARiNG PHARMACY AND ACT4HEALTH JOIN FORCES TO DRIVE MILD COGNITIVE IMPAIRMENT EARLY DETECTION WITH A FREE VISUAL COGNITIVE ASSESSMENT TEST
- Awareness and early-stage detection of Mild Cognitive Impairment (MCI) for prevention. - Free Visual Cognitive Assessment Test (VCAT) screening at selected CARiNG Pharmacy Malaysia outlets. KUALA LUMPUR, Malaysia, July 29, 2024 /PRNewswire/ -- A. Menarini, a wholly owned subsidiary of the M...
2024-07-29 11:20
3058
ALZHEIMER'S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED RECRUITING FOR RESEARCH & REDUCE WAIT TIMES
Key Takeaways * Blood tests that accurately and reliably detect Alzheimer's hallmark brain changes signal a shift to simpler, more accurate and earlier detection and diagnosis, potentially superseding current methods that are expensive, invasive and not always accessible. * A blood test was ...
2024-07-29 08:50
3121
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ERZOFRI® (pa...
2024-07-28 21:48
4150
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation
* The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melano...
2024-07-26 23:21
6607
MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships
JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts inJakarta! MHTC is the pioneer in organising healthcare expo inIndonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two ...
2024-07-26 21:02
6670
ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders
BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a$30 million Series A financing, bringing the total raised so f...
2024-07-26 21:00
4114
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer
* Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved inEurope for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of aChina domestic anti-PD-L1 mAb. * The Eur...
2024-07-26 20:16
10895
MGI and HKBU Collaborate on Advanced Sequencing Technology to Combat Doping in Sports
PARIS, July 26, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced its collaboration with renowned geneticist, Professor Yannis Pitsiladis from Hong Kong Baptist University, on sports a...
2024-07-26 19:35
4284
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
* HanAll reports strong financial performance with second quarter total revenue of31.6 billion KRW, driven by the strong sales from the key products. * HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) ...
2024-07-26 19:00
5449
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 322 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 292 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09